Introduction of “Permission or Prior Intimation” Mechanism for Test Licenses under NDCT Rules, 2026

The NDCT Rules 2026 test license framework introduces a structured permission or prior intimation mechanism, streamlining regulatory oversight for investigational products, APIs, and clinical trial materials manufactured or imported in India.

This regulatory update aims to balance ease of doing research with stronger compliance, aligning India’s clinical trial ecosystem with global best practices while reducing approval timelines for low-risk activities. The NDCT Rules, 2019 originally mandated permission only, with no low-risk fast-track pathway. Industry stakeholders suggested delays in research activities, especially analytical/non-clinical testing.

The Government considered public feedback on the draft notified on 27 Aug 2025, and after review, published the final amendment on 20 Jan 2026.

Background: NDCT Rules 2019 and the 2026 Amendment

The NDCT Rules 2019 established the legal foundation for clinical trials, bioavailability studies, and investigational new drugs in India under CDSCO oversight.

However, increasing research volume highlighted the need for differentiated regulatory pathways, leading to the NDCT Rules 2019 amendment approach formalized through the NDCT Rules 2026.

The amendment introduces clarity on when formal permission is required and when prior intimation to CDSCO is sufficient for test license activities.

Introduction of “Permission OR Prior Intimation” Mechanism

Earlier: Mandatory permission (Form CT-10) for all investigational manufacturing activities

Now: Permission or prior intimation test license system. But

Two routes exist depending on risk category:

 For Higher-risk activities require explicit approval:

• Sex hormones
• Cytotoxic drugs
• Beta-lactams
• Biologics containing live microorganisms
• Narcotics/psychotropic substances
• Clinical Trial and BA/BE study

For Low-risk Activities prior-intimation: 

• Analytical testing 
• Non-clinical testing 
• Manufacturing of APIs or formulations for analysis
  (Except the high-risk categories above)

Applicants submit online CT-10, CT-12 or CT-13 as prior intimation and may start manufacturing immediately on receiving acknowledgment—no waiting for approval.

This approach minimizes regulatory bottlenecks without compromising patient safety or data integrity during clinical trials.

Key Objectives of the Mechanism

Reduce approval timelines for routine testing

• Improve regulatory predictability for sponsors
• Enhance transparency in CDSCO communicationsEncourage domestic clinical research manufacturing
• Reduced Processing Timelines from 90 working days to 45 working days
• Amendments to Forms and Licensing Conditions
  • Forms CT‑10, CT‑12, and CT‑13 are updated to serve both Permission and Prior Intimation pathways.
  • Rule 55 mandates detailed record maintenance, GMP-compliant manufacturing, and usage restrictions prohibiting commercial sale.
  • Rule 61–64 introduce harmonized conditions for manufacturers of formulations and APIs under both permission and prior-intimation categories.
• Expanded Provisions for Suspension and Cancellation
  • Rule 58 and Rule 62 authorize the Central Licensing Authority to suspend or cancel either a permission or a prior-intimation acknowledgment in cases of non-compliance, with an appellate mechanism available.
• Revised Labelling Requirements
  • Under the amended Rule 66, containers must display the manufacturer’s name and address, details of the receiving party, scientific name or reference ID, and manufacturing purpose

Forms and Application Pathways under NDCT Rules 2026

The Form CT-10 application remains central for seeking a test license related to investigational new drugs and APIs.

Depending on the activity, applicants may interact with multiple forms, including Form CT-12 (For Formulation), CT-13 (For API).

Each form corresponds to a specific activity such as manufacturing, import, or testing for clinical trial purposes.

Table 1: Key Forms under NDCT Rules 2026 and Their Use

Impact on Investigational New Drug and API Test License India

The investigational new drug test license process is now more risk-based, offering flexibility to sponsors conducting early-phase or analytical testing.

For API test license India applicants, prior intimation enables faster initiation of laboratory activities without waiting for prolonged approvals.

This is particularly beneficial for CROs, academic institutions, and early-stage biotech companies.

Manufacturing for Clinical Trials India: What Changes?

Manufacturing for clinical trials India is directly impacted, as facilities must now categorize activities under permission or prior intimation routes.

Facilities conducting repetitive or validated processes benefit from reduced administrative burden and improved operational planning.

*New drug and investigational new drug of category of sex hormones, cytotoxic, beta lactum, biologics with live microorganism and narcotics and psychotropic drugs are always required permission irrespective of the activity.

Role of Prior Intimation CDSCO in Regulatory Compliance

The prior intimation of CDSCO pathway mandates timely disclosure, record maintenance, and post-activity reporting when applicable.

Non-compliance may still attract regulatory action, emphasizing that flexibility does not equate to reduced accountability.

Sponsors must maintain robust internal compliance systems to support inspections and audits.

Conclusion and Key Takeaways

The NDCT Rules 2026 reflect India’s evolving regulatory maturity and commitment to research facilitation.

Summary

• NDCT Rules 2026 introduce a risk-based test license mechanism
• Permission or prior intimation depends on activity complexity
• Form CT-10/CT-12/CT-13 remains the primary application route
• API and investigational drug testing benefit from faster initiation
• Compliance and documentation remain critical

In summary, the NDCT Rules 2026 test license regime strengthens regulatory efficiency while supporting innovation in clinical trials, manufacturing, and investigational research across India